Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01998828 | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | terminated | Phase 2 | 39 | Sierra Oncology LLC - a GSK companyINDUSTRY | 5 | Apr 20, 2020 | clinicaltrials |
| NCT00041288 | Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL | terminated | Phase 2 | 10 | University of Texas Southwestern Medical CenterOTHER | 2 | Apr 10, 2020 |
| NCT00901927 | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | terminated | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02727777 | Phase II Study of TAK228 in Relapsed Lymphoma | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | BioInvent International ABINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | terminated | Phase 2 | 6 | Medical College of WisconsinOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT02341495 | Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65(EXJADE) | terminated | Phase 2 | 4 | Elizabeth HenryOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 7 | BayerINDUSTRY | 3 | Feb 26, 2020 | clinicaltrials |
| NCT01749293 | Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation | terminated | Phase 2 | 3 | University of Illinois at ChicagoOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma | terminated | Phase 2 | 11 | NYU Langone HealthOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | terminated | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT00939653 | T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) | terminated | Phase 2 | 6 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT00539656 | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers(Cord Blood) | terminated | Phase 1 / Phase 2 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP(SMR-3184) | terminated | Phase 1 / Phase 2 | 1 | Allarity TherapeuticsINDUSTRY | 1 | Jan 30, 2020 | clinicaltrials |
| NCT04243109 | Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib(POCODEX) | terminated | Phase 2 | 6 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT00899431 | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03269552 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma | terminated | Phase 2 | 4 | University of WashingtonOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02599649 | Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02010645 | Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 3 | Jan 2, 2020 | clinicaltrials |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | terminated | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 27, 2019 | clinicaltrials |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL | terminated | Phase 1 / Phase 2 | 22 | Innate PharmaINDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00582166 | Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance | terminated | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02589145 | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01239368 | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00582816 | Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00691652 | Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02169505 | Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02112045 | A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation | terminated | Phase 2 | 90 | Washington University School of MedicineOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00655668 | A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma(EXPECT) | terminated | Phase 2 | 54 | CelgeneINDUSTRY | 4 | Nov 25, 2019 | clinicaltrials |
| NCT00765102 | Trial of Romidepsin and Bortezomib for Multiple Myeloma | terminated | Phase 2 | 32 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Pharmacyclics LLC.INDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT00117845 | Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01248455 | A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)(ENTO in AML) | terminated | Phase 1 / Phase 2 | 148 | Gilead SciencesINDUSTRY | 3 | Nov 15, 2019 | clinicaltrials |
| NCT03120676 | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | terminated | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02289222 | 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 48 | Ashraf BadrosOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT00866333 | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma(ENGAGE-501) | terminated | Phase 2 | 49 | Syndax PharmaceuticalsINDUSTRY | 1 | Oct 22, 2019 | clinicaltrials |
| NCT01783522 | Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib | terminated | Phase 2 | 9 | Beth FaimanOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | terminated | Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | terminated | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01289210 | VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas | terminated | Phase 1 / Phase 2 | 2 | CelgeneINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT01873495 | Omacetaxine for Consolidation and Maintenance | terminated | Phase 2 | 7 | Emory UniversityOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT02399917 | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01289678 | Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia | terminated | Phase 2 | 18 | Leo W. Jenkins Cancer CenterOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia(8400-401) | terminated | Phase 1 / Phase 2 | 31 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01253460 | Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | terminated | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | terminated | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 20, 2020source: clinicaltrials